Health
Drug Compound Targets Weakness in Advanced Prostate Cancer – Technology Networks
A new study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted using the compound thymoquinone.
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene. Led by researchers at Kanazawa University, the study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted. SUCLA2-deficient prostate cancers represent a significant fraction of those resistant to hormone therapy or metastatic, and a new therapeutic option for this disease would have immense benefits for patient…
-
Noosa News13 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News21 hours agoCountdown on for Noosa Eat & Drink Festival 2025
-
Noosa News18 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News20 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common